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Abstract: Septic morbidity associated with advanced surgical and medical treatments is 
unacceptably high, and so is the incidence of complications occurring in connection with 
acute emergencies such as severe trauma and severe acute pancreatitis. Only considering 
the US, it will annually affect approximately (app) 300 million (mill) of a population of 
almost one million inhabitants and cause the death of more than 200,000 patients, making 
sepsis the tenth most common cause of death in the US. Two major factors affect this, the 
lifestyle-associated increased weakness of the immune defense systems, but more than this 
the artificial environment associated with modern treatments such as mechanical 
ventilation, use of tubes, drains, intravascular lines, artificial nutrition and extensive use of 
synthetic chemical drugs, methods all known to reduce or eliminate the human microbiota 
and impair immune functions and increase systemic inflammation. Attempts to recondition 
the gut by the supply of microorganisms have sometimes shown remarkably good results, 
but too often failed. Many factors contribute to the lack of success: unsuitable choice of 
probiotic species, too low dose, but most importantly, this bio-ecological treatment has 
never been given the opportunity to be tried as an alternative treatment. Instead it has most 
often been applied as complementary to all the other treatments mentioned above, 
including antibiotic treatment. The supplemented lactic acid bacteria have most often been 
killed already before they have reached their targeted organs. 
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1. Introduction: A Pandemic of Critical Illness 
Advanced surgical and medical treatments, as well as medical and surgical emergencies, are, 
despite some breath-taking advances in medico-pharmaceutical and surgical treatment, still 
accompanied by an unacceptably high morbidity and also mortality. Worse than this, morbidity and 
mortality in these conditions is fast increasing and has done so all over the world for several decades. 
Apart from the suffering associated with this, it is also extremely costly to the individual and the health 
care system. 
Dominating among the treatment-induced morbidities is sepsis due to bacterial, fungal or viral 
infections. Recent observations in the US suggest that not only the incidence, but also the severity of 
sepsis, has significantly increased during the last decades [1–3]. Especially advanced surgery carries a 
high rate of septic morbidity and especially esophageal, pancreatic, and gastric procedures are 
particularly known to represent great risk for the development of sepsis, but thoracic, adrenal, and 
hepatic procedures are those that have the highest sepsis-induced mortality [1,2]. It is also documented 
in the literature that elderly patients, men, and nonwhites are the most likely to develop sepsis as a 
complication to surgical treatment [1,2]. Sepsis is by far the most common medical and surgical 
complication, and estimated only in the US to annually affect as many as 751,000 [4,5], and cause 
death of app 215,000 patients (29% of treated patients) [5], making sepsis the tenth most common 
cause of death in this country. 
2. Sepsis: Often a Product of So Called Auxiliary/Supportive Measures 
Post-surgical morbidity and due to septic manifestations is only partly attributed to the surgeon and 
the surgical technique. Increasing evidence suggests instead that it is the patient’s ability to resist 
disease/immune defense and especially supportive measures during and around the treatment, such as 
mechanical ventilation, use of implants, drains and intravascular lines, but also choice of content and 
routes to provide nutrition, blood transfusions, choice of anesthesia and prescription of drugs, also 
antibiotics and immune-suppressives, that are the largest contributors to the development of 
septic manifestations.  
Mechanical ventilation in association with management of emergencies and surgical procedures has 
in recent years received increasing attention as a major contributor to chest-infections, but also to 
general and localized septic manifestations in the body; according to a recent study applied in the US 
in about 800,000 individuals every year. It is estimated to represent no less than 12% of total hospital 
costs, no less than $27 billion in the US alone [6]. This treatment is responsible for, not only a 
disproportional amount of resources used, but also for the unacceptably high morbidity and mortality 
associated with the treatment, especially in elderly people [6].  
A main contributor to intensive care unit (ICU)-associated sepsis is also artificial nutrition, both 
enteral and parenteral; catheter-related sepsis is reported to occur in about 25% of patients fed via 
intravenous feeding-tubes [7]. Numerous drugs used in the ICUs including antibiotics are known to 
derange the immune functions, impair macrophage functions, bactericidal efficacy as well as 
production and secretion of cytokines. For example, supply of an antibiotic, Mezlocillin (Bayer,   
150 mg/kg body weight) is demonstrated to significantly suppress essential macrophage functions and Nutrients 2012, 4  93 
 
 
derange chemiluminescence response, chemotactic motility, bactericidal and cytostatic ability and 
impair lymphocyte proliferation [8]. Other common perioperative practices like use of artificial 
feeding regimens, preoperative antibiotics [9], and mechanical bowel preparation [10,11] will also, 
according to recent studies, instead of the expected prevention as expected, contribute to increased 
rates of treatment-associated infections.  
3. Gut and Chest Infections Dominate 
Most of the surgical infections originate in areas with the most exposure to the exterior world,  
i.e., the gut (63%) and chest (20%) and are pure gram-negative (22%), pure gram-positive (15%), 
mixed (23) or fungal (8%) [12]. It is also here that the dominating parts of the immune functions are 
localized: between 70–80% of the Ig-producing immunocytes of the body are found in the gut [13]. It 
was Marshall and his group who, in 1993, directed attention to the gut as a special source of surgical 
sepsis and especially to its most severe form—multiple organ failure (MOF) [14]. They observed that 
the most common organisms to cause ICU-acquired infections—Candida,  Streptococcus faecalis, 
Pseudomonas, and coagulase-negative Staphylococci—were also the most common species that 
seemed to colonize especially the proximal GI tract. They reported that this colonization correlated 
well with development of invasive infection within one week: Pseudomonas (90% vs. 13% in   
non-colonized patients, p < 0.0001) and Staphylococcus epidermidis (80% vs. 6%, p < 0.0001). As a 
consequence of these observations, they coined the phrase: “the gut—the undrained abscess”. Studies 
during subsequent years focused mainly on microbial translocation as the major course of sepsis.  
Important observations had, however, been made by Baue, Faist and their groups already ten years 
earlier, and their finding that a significant portion of patients, who develop multiple organ dysfunction 
syndrome (MODS), and do not have an identifiable infection [15], should have a great impact on 
future understanding of treatment and emergency-associated sepsis. It was Goris and his collaborators, 
who, in 1986, based on observations like those of Baue and Faist, but also after extensive studies in 
animals, suggested inflammation precedes septic manifestations and an “auto-destructive inflammatory 
response” with or without bacterial infection, is a major cause of this severe condition [16].  
4. Preceding Uncontrolled Exuberant Systemic Inflammation  
Patients who develop severe septic complications are known to respond to physical and mental 
stress with an early exuberant acute, or chronic, super-inflammation, with signs of exaggerated and 
prolonged release of pro-inflammatory cytokines such as interleukin-6 (IL-6), acute phase proteins 
such as C-reactive protein, and plasminogen activator inhibitor 1 (PAI-1)—see [17]—a reaction 
strongly associated with subsequent severe exacerbation of disease, including acute respiratory distress 
syndrome (ARDS), and MOF. Among the observed changes associated with an exuberant inflammation 
in the early nervous phase are: augmented endothelial adhesion of polymorphonuclear (PMN) cells, 
increased production of intracellular adhesion molecule-1 (ICAM-1), priming of the PMNs for an 
oxidative burst, release of pro-inflammatory platelet activating factor (PAF), and a delay in PMN 
apoptosis [18]. Visceral adipocytes are, compared to subcutaneous fat cells, known to secrete per gram 
tissue much more of free fatty acids but also about three times as much IL-6, and PAI-1; observations 
that well explain the high risk of both chronic and acute diseases in individuals with visceral Nutrients 2012, 4  94 
 
 
obesity [19]. The stress-induced load of these and other proinflammatory and procoagulant molecules 
on organs, such as the lung and the liver, can vary a thousand times or more, as the amount of fat in the 
abdomen can vary from a few milliliters in a lean subject to about six liters in gross obesity [20].  
5. Mental and Physical Stress Potentiates the Response 
An increase in growth of Gram-negative bacteria of up to 100,000 times (5 logs of order) has been 
demonstrated in animals exposed to noradrenaline; see Lyte’s review [21]. Old observations suggest a 
strong and significant association between higher blood levels of noradrenaline and adrenaline and 
development of severe septic conditions [22]. Luminal release of noradrenaline is a documented strong 
inducer of virulence of luminal bacteria [23], and much suggests that potentially pathogenic 
microorganisms (PPMs), normally indolent colonizers, under stress change their phenotype and 
become life-threatening pathogens [24]. These observations are particularly interesting as classical 
studies published already in the 1940s demonstrated that a 10,000 times lower dose of Clostridium 
welchii is needed to induce death in gas-gangrene in animals, when also adrenaline is administered to 
the animals [25]. Most likely similar potentiating effects exist when stress and stress-hormones are 
applied also to other pathogenic bacteria.  
6. Deranged and Dysfunctioning Microbiota 
Microbiota is significantly reduced in Westerners. A study published in the US in 1983 reported 
that Lactobacillus plantarum, a dominating lactic acid bacterium (LAB) among plant eaters, is found 
in only about 25% of omnivorous Americans and in about two thirds of vegetarian Americans [26]. A 
more recent Scandinavian study suggest that also in healthy individuals, the most common colonic 
LAB are present in only half or less of the individuals: Lactobacillus plantarum in 52%, Lactobacillus 
rhamnosus in 26% and Lactobacillus paracasei ssp. paracasei 17% [27]. Western lifestyle with frequent 
mental and physical stress, and eating of processed foods with high content of saturated fats and  
trans-fatty acids, lack of dietary fibers, containing chemicals and pharmaceuticals, but also lack of 
microorganisms content in food, will significantly reduce the microbiota both with regard to diversity 
and extent of existing flora. Recent studies report that in Westerners, a significant shift in balance from 
gram-positives to gram-negatives, and subsequent increase in production of endotoxins/lipopolysaccharide 
(LPS) [28]. Magnesium (Mg) requirements are known to be much higher for Gram+ than for Gram− 
bacteria and Mg deficiency, common in Westerners, was recently shown to induce decreased content 
in the gut especially of Bifidobacteria, to increase colonic and systemic inflammation, and increase 
intestinal permeability. These observations are of particular interest as Mg deficiency is associated 
with systemic inflammation and common metabolic disorders such as type 2 diabetes, metabolic 
syndrome, dyslipidemia, and hypertension [29], but also observed in ICU patients. Mg-deficient 
patients, in comparison to patients with normal magnesium levels, are reported to exhibit a higher 
prevalence of severe sepsis and septic shock (57 vs. 11%, p < 0.01), a longer ICU stay (15.4 ± 15.5 vs. 
2.8 ± 4.7 days, p < 0.01), and a higher mortality rate [30]. 
A several log-fold decrease in the commensal bacteria like Bifidobacteria and Lactobacilli are 
reported in trauma patients in parallel to increased populations of pathogenic bacteria such as 
Pseudomonas aeruginosa and Staphylococcus aureus [31]. The Western lifestyle-induced derangement Nutrients 2012, 4  95 
 
 
of the microbiota is associated with increased permeability of intestinal mucosa, increased LPS 
absorption, increased endotoxemia, exaggerated inflammation, and strongly associated with metabolic 
disorders such as obesity and diabetes [32]—conditions, which also are commonly associated with 
increased surgical morbidity, surgical infections and MOF. 
7. Overreacting Neutrophils 
Severe trauma, major surgery and severe sepsis will, parallel to a significant decrease in 
lymphocytes, induce a significant, sometimes disproportionate, increase in circulating and tissue 
neutrophils, and be accompanied by persistent decline in T-4 helper lymphocytes and elevation of T-8 
suppressor lymphocytes [33]. It is suggested that a T-4/T-8 lymphocyte cell ratio of <1 is a sign of 
severe immunosuppression and predictor of complication, such as multiple organ dysfunction 
syndrome, myocardial infarction, acute pancreatitis, multiple severe trauma and chemotherapeutic 
treatment, especially in oncology patients [34]. An early and large increase in circulating neutrophils is 
accompanied by tissue infiltration of neutrophils, and responsible for common posttrauma/postoperative 
dysfunctions such as paralytic ileus [35,36], bone marrow suppression, endothelial cell dysfunction, 
and to lead to tissue destruction and organ failure, particularly in lungs [37–39], intestines [40], 
liver [41] and kidney [42]. Neutrophil infiltration of distant organs [16], especially the lungs [37], is a 
characteristic finding in patients dying of sepsis. The extent of neutrophil infiltration is significantly 
aggravated by mechanical therapeutic efforts such as handling of the bowels during operation [35], and 
ventilation of the lungs [43]. Poor nutritional status, preexisting immune deficiency, obesity, diabetes 
and high levels of blood sugar [44] contribute to immune deterioration and to increased expressions in 
the body of molecules such as NF-κB, COX-2, LOX and iNOS [45,46]. The disproportionate increase 
in circulating neutrophils is to a great extent inhibited by supplementation of antioxidants [47,48] and 
specific probiotics [49].  
Supplementation of probiotics will effectively prevent neutrophil infiltration of the lung and also 
reduce the subsequent tissue destruction, as demonstrated in studies with inflammation induced by 
cecal ligation and puncture (CLP). A synbiotic formulation, Synbiotic 2000 Forte (see further below), 
was administered orally before the induced trauma and effectively prevented both neutrophil 
accumulation and tissue destruction in the lungs [50]. Most interestingly, these effects were obtained 
also when the LAB of the composition were injected subcutaneously (Figures 1–3) [51].  
The average neutrophil count in the lungs (average of five fields) was: mixture of LAB and 
bioactive fibers 9.00 ± 0.44 (1), only LAB 8.40 ± 0.42 (2), only bioactive fibers 31.20 ± 0.98 (3), 
placebo (non-fermentable fiber) 51.10 ± 0.70 (4). The reduction of inflammation by the treatment was 
also demonstrated by significant reductions in myeloperoxidase (MPO), malondialdehyde (MDA), and 
nitric oxide (NO): MPO being 25.62 ± 2.19 (1), 26.75 ± 2.61 (2), 56.59 ± 1.73 (3), and 145.53 ± 7.53 (4) 
respectively (resp.), MDA 0.22 ± 1.31 (1), 0.28 ± 3.55 (2), 0.48 ± 5.32 (3) and 0.67 ± 2.94 (4) resp. 
and NO 17.16 ± 2.03 (1), 18.91 ± 2.24 (2), 47.71 ± 3.20 (3) and 66.22 ± 5.92 (4) resp.—all differences 
being statistically significant (>0.05). Nutrients 2012, 4  96 
 
 
Figure 1. Control group. 
 
Figure 2. Synbiotic treated group. 
 
Figure 3. Prebiotic group. 
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8. Personal Experience with Pro- and Synbiotics 
My interest in microbiota and probiotics stems back to 1986. Since 1963, I was a surgeon focusing 
my interest on liver surgery, and was actively searching for new tools to combat the unacceptably high 
rate of perioperative infections associated with major surgery and particularly with extensive liver 
resections. A review of our last 81 liver resections yielded some unexpected information, which 
directed my interest to human microbiota and probiotics. It was standard practice at that time, in 
connection with surgery, to provide the patients with an antibiotic umbrella for at least five days with 
the hope that this treatment might somewhat reduce the rate of infections. The shocking information 
from this study was that only 57/81 patients had in fact received this treatment, while the treatment had 
been neglected in as many as 24/81 patients [52,53]. However, the unexpected information from this 
review was that there were no cases of sepsis reported in the patients who had not received 
prophylactic antibiotics. As a matter of fact, all manifestations of sepsis had occurred in the   
antibiotic-treated patients. A growing awareness of the importance of human microbiota [54] and the 
eventual possibility of reconditioning of the gut through probiotic treatment [55] was at that time 
visible. It was also increasingly understood that lifestyle, chemicals and pharmaceuticals, in addition to 
the disease per se, could impair the microbiota and immune defense.  
It seemed likely that powerful probiotic treatment could constitute an effective prevention of 
unwanted infections in disease and also in surgical and emergency medical cases. That was the reason 
why I established collaboration with experts in microbiology, chemistry, nutrition, experimental and 
clinical science to seek opportunities find, develop and test, experimentally and clinically, probiotics, 
which could be expected to be powerful tools to prevent sepsis. Our first efforts resulted in a one 
LAB/one fiber composition, produced by fermentation of oat meal with Lactobacillus plantarum strain 
299 [56–58]. I worked with this synbiotic composition for more than ten years. This formula is 
produced and marketed by Probi AB, Lund, Sweden. 
After 1999 and until today, I have continued my research with a four LAB/four fiber composition, 
which consists of a mixture of 10
10 (standard version—Synbiotic  2000™) and a mixture of 10
11  
(forte version—Synbiotic 2000 forte™) of four different LAB: Pediococcus pentosaceus 5-33:3, 
Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus 
plantarum 2362 combined with 10 g of fibers; 2.5 g of each of four fermentable fibers: betaglucan, 
inulin, pectin and resistant starch [59,60]. The standard Synbiotic 2000 contains thus 4 × 10 billion 
LAB = 40 billion and the stronger version, Synbiotic 2000 forte, 4 × 100 billion LAB = 400 billion 
resp. of lactic acid bacteria. The formula is marketed by Ionian Pharma, Glyka Nera, Greece and 
Synbiotic AB, Höganäs, Sweden.  
8.1. Early Treatment in Major Trauma 
Two prospective randomized trials with Synbiotic 2000 and Synbiotic 2000 Forte respectively have 
been concluded. The first study compared in-patients with acute extensive trauma receiving four types 
of treatment: (1) Synbiotic 2000 (40 billion LAB/day); (2) A soluble fiber; (3) A peptide diet 
(Nutricomp, Braun Inc. Germany); and (4) Glutamine supplementation. Treatment with Synbiotic 
2000™ led to a highly significant reduction in number of chest infections (4/26 patients—15%) Nutrients 2012, 4  98 
 
 
compared to peptide diet (11/26 patients—42%, p < 0.04), glutamine treatment (11/32 patients—34%, 
p < 0.03) and only fiber treatment (12/29 patients—41%, p < 0.002) [61]. Also the total number of 
infections was significantly decreased: Synbiotic 2000™ 5/26 patients (19%), peptide 13/26 patients 
(50%) glutamine16/32 patients (50%) and only fibers 17/29 patients (59%).  
In another study, 65 polytrauma patients were randomized to receive either Synbiotic 2000 Forte 
(400 billion LAB + 10 gram of fibers, see above) or maltodextrine as placebo, once daily, for 15 days. 
Significant reductions were observed in number of deaths (5/35 vs. 9/30, p < 0.02), severe sepsis (6/35 
vs. 13/30, p < 0.02), chest infections (19/35 vs. 24/30, p < 0.03), central line infections (13/32 vs. 
20/30,  p < 0.02), and ventilation days (average 15 vs. 26 days [62]). A total of pathogenic 
microorganisms of 54 were cultivated in the Synbiotic treated group compared to 103 in the fiber-only 
group [63,64]. Repeat analyses also revealed that serum levels of endotoxin (lipopolysaccharide 
(LPS)) were decreased and time to bloodstream infection significantly prolonged in patients treated 
with Synbiotic 2000 forte. 
8.2. Early Treatment in Severe Acute Pancreatitis 
Patients with severe acute pancreatitis were randomized to receive, during the first 7 days   
daily administered through a nasojejunal tube, either a freeze-dried preparation containing live   
Lb plantarum 299 in a dose of 10
9 together with a substrate of oat fiber or a similar preparation, but 
heat-inactivated [65]. The study was concluded when, on repeat statistical analysis, significant 
differences in favor of one of the two groups were obtained. This occurred when a total of 45 patients 
had entered the study. 22 patients had at that time received treatment with live and 23 with the   
heat-killed Lb plantarum 299. Infected pancreatic necrosis and abscesses were seen in 1/22 (4.5%) in 
the live LAB group vs. 7/23 (30%) in the heat-inactivated group (p = 0.023). The only patient in the 
lactobacillus group, who developed infection, a urinary infection, did that on the 15th day, e.g., at a 
time when he had not received treatment for eight days. The length of stay was also considerably 
shorter in the live LAB group (13.7 days vs. 21.4 days), but the limited size of the material did not 
allow statistical significance to be reached. 
Sixty-two patients with severe acute pancreatitis (SAP) (Apache II scores: Synbiotic 2000-treated 
11.7 ± 1.9, controls 10.4 ± 1.5) were given either two sachets/day of Synbiotic 2000™ (2 × 40 billion 
LAB/day and totally 20 g fibers) or the same amounts of fibers (20 g) as in Synbiotic 2000™ during 
the first 14 days after arrival to the hospital [66]. 9/33 patients (27%) in the Synbiotic 2000-treated 
group and 15/29 patients (52%) in the only fiber-treated group developed subsequent infections.   
Eight out of 33 (24%) Synbiotic 2000-treated patients, and 14/29 (48%) of the only fiber-treated 
patients, developed systemic inflammatory response syndrome (SIRS), MOF or both (p < 0.005). A 
total of pathogenic microorganisms of seven were cultivated in the Synbiotic-treated group compared 
to 17 in the only-fiber group.  
8.3. Effects on “Mind Clarity”: Encephalopathy 
Patients with critical illness, as well as patients with chronic disorders such as liver cirrhosis and 
diabetes, often suffer a mild, but sometimes, severe confusion, which often has its origin in the   
gut [67]. Increasing evidence suggest that probiotics, alone and/or in combination with plant antioxidants Nutrients 2012, 4  99 
 
 
and fibers, possess strong neuro-endocrine modulatory effects and alleviates effects of physical and 
mental stressors both early [68] as well as later in life [69]. We undertook some studies to explore the 
effects of synbiotic treatment in patients with liver cirrhosis and minimal hepatic encephalopathy (MHE).  
Fifty-five patients with MHE were randomized to receive, for 30 days: (1) Synbiotic 2000 (n = 20),  
(2) The fibers in the composition alone (n = 20), or (3) Placebo (n = 15). All cirrhotic patients with 
MHE were found to have severe derangements of the gut micro-ecology, and significant overgrowth of 
potentially pathogenic Escherichia coli and Staphylococcal species. Synbiotic treatment increased the 
fecal content of non-urease-producing Lactobacillus species significantly and reduced the numbers of 
potentially pathogenic micro-organisms. The treatment was also associated with a significant reduction 
in endotoxemia and in blood ammonia levels. A documented reversal of MHE was obtained in half of 
the treated patients; the Child-Turcotte-Pugh functional class improved in about 50% of cases [70]. 
Treatment with fermentable fibers alone also demonstrated substantial benefit in a proportion of patients. 
Thirty cirrhotic patients were randomized in a second study to receive Synbiotic 2000 or placebo 
for only 7 days. Viable fecal counts of Lactobacillus species, Child-Pugh class, plasma retention rate 
of indocyanine green (ICGR15), whole blood tumor necrosis factor alpha (TNF-a) mRNA and IL-6 
mRNA, serum TNF-a, soluble TNF receptor (sTNFR)I, sTNFRII, IL-6 and plasma endotoxin levels 
were measured pre- and post-treatment. The treatment with Synbiotic 2000 was associated with 
significantly increased fecal lactobacilli counts and significant improvements in ICGR15 and   
Child-Pugh class [71]. Significant increases in whole blood TNF-a mRNA and IL-6 mRNA, along 
with serum levels of sTNFRI and sTNFRII, were also observed and TNF-a and IL-6 levels correlated 
significantly, both at baseline and post-synbiotic treatment [71]. Synbiotic-related improvement in 
ICGR15 was significantly accompanied by changes in IL-6, both at mRNA and protein levels, but was 
unrelated to levels of plasma endotoxin. No significant changes in any parameter were observed 
following placebo treatment. Even this study concluded that short-term synbiotic treatment modulates 
gut flora significantly and improves liver function in patients with cirrhosis.  
9. Studies by Others 
In a recent study twenty-nine SIRS patients with a serum C-reactive protein (CRP) level above  
10 mg/dL, received a synbiotic composition consisting of Bifidobacterium breve and Lactobacillus 
casei, in combination with galactooligosaccharides. The incidence of infectious complications such as 
enteritis, pneumonia, and bacteremia were (compared to historical controls) significantly lower in the 
treated group [72]. Analysis of fecal flora demonstrated significantly higher levels of Bifidobacteria 
and Lactobacillus, and also of total organic acids, particularly short-chain fatty acids.  
10. Studies with No, or Adverse, Effects 
10.1. Ecologic 641™ 
Two hundred and ninety eight patients with predicted severe acute pancreatitis and with APACHE 
II score ≥8, Imrie score > 3, or C-reactive protein >150 mg/L) within 72 h of onset of symptoms were 
included in a multicenter, double-blind, placebo-controlled trial, randomly assigned to receive either a 
multispecies probiotic preparation (n = 153) or placebo (n = 145), administered enterally twice daily Nutrients 2012, 4  100 
 
 
for 28 days. The probiotic composition supplemented, Ecologic 641 (Winclove Bio Industries, 
Amsterdam, The Netherlands), consisted of 10
10 of each of six different strains of freeze-dried, viable 
bacteria: Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius, Lactococcus lactis, 
Bifi dobacterium bifidum, and Bifidobacterium lactis. It contained also cornstarch and maltodextrins. 
The subsequent analyses were based on 152 individuals in the treated group and 144 in the placebo 
groups. Infectious complications occurred in 46 (30%) of patients in the probiotics group and in 
41 (28%) of those in the placebo group (relative risk 1.06, 95% CI 0.75–1.51). Twenty-five (16%) 
patients in the probiotics group died, compared to nine (6%) in the placebo group (relative risk 2.53, 
95% CI 1.22–5.25) [73]. Furthermore, nine patients in the probiotics group developed bowel ischemia, 
eight of which with fatal outcome, compared to none in the placebo group (p = 0.004). 
10.2. Lactobacillus plantarum 299™: ProViva™ 
One hundred and three critically ill patients were randomized to receive 1 ProViva, a fruit drink 
containing 5% of LAB-fermented oat and live Lactobacillusb plantarum 299v with a density of   
5 × 10
7 (n = 52) or conventional nutrition therapy alone (n = 51). The treatment demonstrated no 
identifiable effect in terms of bacterial translocation (12% vs. 12%; p = 0.82), gastric colonization with 
enteric organisms (11% vs. 17%, p = 0.42), or septic morbidity (13% vs. 15%; p = 074), serum CRP 
levels or mortality [74]. In another study, 11 patients undergoing elective abdominal surgery during a 
median time of 9 days (range 5–18 days) received lactobacillus 299v (ProViva) to total average 
amounts of 3250 mL (range 2100–9000 mL), and were compared to 11 control patients. The authors 
found no significant differences between the ProViva group and the control group in terms of 
concentrations of plasma cells, IgA positive cells or IgM positive cells in the lamina propria [75]. 
There was a significantly higher concentration of IgM at the mucosal surface in the control group  
(P = 0.02, Fishers Exact test mid P), but no difference in terms of IgA.  
10.3. Lactobacillus rhamnosus GG™ 
Sixty-one patients were in a study in pediatric ICU, randomized: 31 patients to receive treatment 
with one capsule of Lactobacillus rhamnosus strain GG in a dose of 10
10, and 30 patients to receive 
one capsule with insulin daily (control group). No difference in rate of infections was observed 
between the groups; the mean number of infections in the treatment and control groups was 1.83 and 
1.33, respectively. 9/31 patients in the probiotic-treated group developed in total 15 nosocomial 
infections: six bloodstream infections (40%), five tracheo-bronchitis (33%), two pneumonia (13%), 
and two UTI (13%) [76]. There were totally six deaths during the study period; four in the placebo 
group and two in the treatment group. No cases of Lactobacillus bacteremia or other serious adverse 
effects were observed.  
10.4. Synbiotic 2000™/Synbiotic 2000 Forte™ 
Synbiotic 2000 (40 billion LAB) was given daily to 162 patients and 168 control patients received 
similarly only the fibers of the synbiotic composition. No significant differences in demographics, 
mortality (ICU or hospital), morbidity, maximal multiple organ dysfunction (MOD) score, ICU length Nutrients 2012, 4  101 
 
 
of stay, diarrhea days or septic complications were observed between intervention and control   
groups [77]. Similarly post hoc analysis of those patients who received at least 75% of prescribed 
doses revealed no difference in ICU mortality (21% vs. 20%) or hospital mortality (32% vs. 26%) 
between the intervention and control groups. It was especially noted that no episodes of intestinal 
ischemia were observed in either group. 
Two hundred and fifty nine enterally fed critically ill patients, expected to require mechanical 
ventilation for 48 h or more were enrolled in a study; 130 patients received Synbiotic 2000 FORTE
® 
(twice a day) and 129 patients a cellulose-based placebo for a maximum of 28 days. The oropharyngeal 
microbial flora and colonization rates were unaffected by the synbiotic treatment. The overall 
incidence of ventilator associated pneumonia (VAP) was lower than anticipated (11.2%) and no 
statistical difference was demonstrated between the groups receiving synbiotic or placebo; incidence  
of VAP (9 and 13%, P = 0.42), VAP rate per 1000 ventilator days (13 and 14.6, P = 0.91) or hospital 
mortality (27 and 33%, P = 0.39), respectively [78]. No negative effects of the treatment 
were observed.  
10.5. Trevis™ 
A total of 90 patients admitted to an ICU were randomized to receive either synbiotic or placebo 
(45 into each group). The synbiotic treatment consisted of supplying, three times a day, a capsule of 
Trevis
TM (Chr Hansen Biosystem, Denmark), containing 4 × 10
9 colony forming units of each of  
L. acidophilus La5 (La5), B. lactis Bb-12 (Bb-12), S. thermophilus and L. bulgaricus. In addition the 
prebiotic oligofructose (7.5 g of RaftiloseTM powder, Orafti Active Food Ingredients, Belgium) was 
administered twice a day. The patients in the synbiotic group demonstrated after 1 week of therapy 
significantly lower incidence of potentially pathogenic bacteria (43% vs. 75%, P = 0.05) and multiple 
organisms (39% vs. 75%, P = 0.01) in their nasogastric aspirates than the controls [79]. However,  
there were no significant differences between the groups in terms of intestinal permeability, septic 
complications or mortality.  
10.6. VSL#3™ 
Twenty-eight patients were enrolled and randomly assigned to one of three treatment groups:   
(1) placebo (n = 9); (2) viable probiotics—2 sachets daily of VSL#3™ (n = 10); or (3) bacterial 
sonicates—not viable VSL#3 bacteria (n = 9). Each sachet of the supplemented probiotic, VSL#3 
(VSL Pharmaceuticals, Ft Lauderdale, FL) contains 900 billion viable lyophilized bacteria of 4 strains 
of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus) plus 
3 strains of Bifidobacterium (B. longum, B. breve, and B. infantis), plus Streptococcus salivarius subsp. 
Thermophiles, totally eight strains. Intestinal permeability decreased in all treatment groups. The rate 
of severe sepsis and MODS were not significantly affected by the treatment, although a significantly 
larger increase in systemic IgA and IgG concentrations were observed in the group supplied with live 
bacteria than in the patients who received placebo or sonicated bacteria (P < 0.05) [80].  Nutrients 2012, 4  102 
 
 
11. Why do Studies Fail? 
Critical care units are in general a highly artificial environment and the burden of environment-induced 
physical and mental stress and subsequent status of systemic hyper-inflammation on the patient is 
unbearable. Patients treated under these conditions are in many aspects dysfunctional, the whole 
microbiota is gone and probiotic bacteria supplied will most often be killed already before they have 
reached its target organ. This artificiality seems to vary from country to country, and sometimes also 
from hospital to hospital, observations that might explain the great variation in outcome from studies 
undertaken in different regions and countries.  
Probiotic treatment has never been given the chance as an alternative treatment; it has only been 
tried as a treatment complementary to all the other standard treatments. As discussed above, a series of 
auxiliary measures and particularly mechanical ventilation [7] and treatment with various drugs, 
including antibiotics [8,9], but also clinical nutrition solutions belong to those factors which promote 
super-inflammation and, indirectly, infection. Enteral nutrition formulas are also known to induce loss 
of intestinal barrier function, promotes bacterial translocation, and impairs host immune defense [81], 
a phenomenon, observed in humans and further elucidated in animal studies. The incidence of bacterial 
translocation to the mesenteric lymph node was in such studies significantly increased when the 
animals were fed nutrition formulas such as Vivonex (53%), Criticare (67%), or Ensure (60%)   
(p < 0.05) [82–84]. Similar observations have also been made in patients. Significant elevations in  
pro-inflammatory cytokines were observed in patients, who after pancreatoduodenectomy are fed a 
standard enteral nutrition solution (Nutrison): IL-1beta—day 7 (P < 0.001), day 14 (P = 0.022);   
TNF-alpha—day 3 (P = 0.006), day 7 (P < 0.001) [85]. Of special interest are the observations that 
such changes were not observed when the standard nutrition was replaced with a formula that claimed  
to have immune-modulatory effects (Stresson). Instead anti-inflammatory cytokines were seen 
significantly elevated: IL-1ra/s: day 7 (P < 0.001), IL-6: day 10 (P = 0.017), IL-8: day 1 (P = 0.011) 
days 3, 7, 10, and 14 (P < 0.001) and IL-10: days 3 and 10 (P < 0.001). 
The type of bacteria to be chosen for probiotic purpose is also critical. Only a few LAB strains have 
demonstrated ability to influence the immune system, reduce inflammation and/or eliminate or reduce 
unwanted pro-inflammatory molecules from foods. Even strains, which carry sometimes the same 
name have often different and sometimes opposite effects. A recent study selected 46 strains of 
Lactococcus lactis from about 2600 LAB and compared their ability to induce cytokines. It was 
demonstrated that the inter-strain differences in ability to produce pro- and anti-inflammatory 
cytokines were great [86], an observation which underlines the importance of extensive animal and 
preclinical studies before a LAB or combination of LAB be chosen as probiotic. 
12. Choice of Lactic Acid Bacteria as Probiotics 
Especially desirable as probiotics are strains that improve immune function by increasing the 
number of IgA-producing plasma cells, improve phagocytosis, and influence the proportion of Th1 
cells and NK cells [87]. Among the strains with a strong anti-inflammatory record are Lactobacillus 
paracasei subsp. paracasei,  Lactobacillus plantarum, and Pediococcus pentosaceus. Especially 
Lactobacillus paracasei seems to have a solid record. It has been shown to induce cellular immunity, Nutrients 2012, 4  103 
 
 
stimulating the production of suppressive cytokines such as TGFβ and IL-10; to suppress Th2 activity, 
CD4 T-cells [88,89], and splenocyte proliferation [90]; and to decrease antigen-specific IgE and   
IgG1 [91]. Lactobacillus paracasei was shown to be the strongest inducer of Th1 and repressor of Th2 
cytokines when more than a hundred LAB strains were compared [92]. A recent study in rats 
compared the ability of four different strains: Lactobacillus paracasei,  Lactobacillus johnsonii, 
Bifidobacterium longum, or Bifidobacterium lactis to control Trichinella spiralis—induced infection. 
Lactobacillus paracasei, but none of the others, were able to reduce infection-associated Th2   
response, muscle levels of TGF-β, COX-2 and PGE2 and to attenuate infection-induced muscle   
hyper-contractility [93]. Another recent study compared the ability to reduce stress-induced changes in 
gut permeability and sensitivity to colorectal distension of three probiotic strains: Bifidobacterium 
lactis  NCC362,  Lactobacillus johnsonii NCC533, and Lactobacillus paracasei NCC2461. 
Lactobacillus paracasei but none of the other LAB, significantly restored normal gut permeability, and 
reduce visceral hyperalgesia and visceral pain [94].  
Lactobacillus plantarum has also an excellent record. When the ability of fifty different LAB to 
control twenty-three different Clostridium difficile (C diff) strains  were studied, Lactobacillus 
paracasei and Lactobacillus plantarum were the only strains with ability to effectively eliminate all 
C. diff strains—more than half of the tried LAB strains were totally ineffective, and some only against 
a few [95]. Some LAB can be potentiated in their efficacy by simultaneous supply of prebiotic fibers 
(probiotics + prebiotics ≥ synbiotics). However, there are great differences in the ability of different 
strains to ferment and utilize plant fibers, especially when it comes to semi-fermentable fibers such as 
oligofructans. Only a handful of LAB from the 712 tested strains demonstrated in a study ability to 
ferment inulin and phlein, namely: Lactobacillus plantarum (several strains), Lactobacillus paracasei 
subsp. paracasei, Lactobacillus brevis and Pediococcus pentosaceus [96]. 
13. Discussion: The Future “Designer Probiotics”? 
Two recent studies provide a fascinating insight into the future. Gene expression of human 
duodenal mucosa cells were studied after exposure to one of the following four lactic acid bacteria: 
Lactobacillus plantarum WCFS1 [97], Lactobacillus acidophilus L10, Lactobacillus casei CRL-431 
and L. rhamnosus GG [98], administered in a cross-over study to healthy volunteers in a dose of 10
10. 
Mucosal biopsies were taken from duodenum after 6 h and compared to control biopsies. The 
interventions did not impair immune and metabolic homeostasis. Nevertheless, a fascinating and most 
distinct influence on expression of several hundred genes (transcriptome) was reported after 
administration of each of the LAB. For seemingly the first time, different probiotic lactobacilli are 
reported to induce more or less strain-specific and markedly different expression profiles, much similar 
to what is known to occur with ingestion of various foods, especially plant ingredients [99,100], but 
also similar to the effects observed after supplying certain pharmaceuticals. Thus L. plantarum was 
reported to modulate overt adaptive immune responses [97], L. acidophilus to suppress inflammation, 
L. casei to stimulate Th1 response and improve the Th1–Th2 balance, L. rhamnosis to influence 
cellular growth and proliferation [98]. The effects were suggested to resemble, although distinctly 
milder, those obtained by specific pharmaceuticals: L. acidophilus—antagonists of α-receptor activity, 
guanine antagonists, synthetic corticosteroids and flavonoids, L. casei—modulators of GABA receptors, Nutrients 2012, 4  104 
 
 
cholinergic blocking agents, antagonists of β-adrenergic receptors, L. rhamnosus—glycoside steroids, 
alkaloids, protein synthesis inhibitors and protein kinase C inhibitors. A large person-to-person 
variation in response was also reported. 
The responsiveness to ingestion of various LAB seems to be strongly influenced, not only by eventual 
genetic background and existing resident microbiota, but also by lifestyle, and particularly by diet, 
which might explain the person-to-person differences in response observed in the above studies [97,98], 
but also differences in outcome, when applied in critically ill patients, as reported in this review. 
In the immediate future, probiotics will most likely continue to find its dominating niche as 
treatment given to rather healthy and health-concerned individuals with the main aim to promote 
health and prevent disease. However, it is likely that probiotics, as our knowledge in nutragenomics 
and therapeutic microbiology increases, will be generally regarded also as valuable tools for treatment 
of various acute and chronic diseases, also in critically ill patients. The review of studies reported to 
date and presented in this review supports such an assumption. Probiotics will, however, not be 
generally accepted and utilized as clinical tools until radical and profound changes in treatment 
practices in care of the critically ill and other patient groups are implemented.  
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